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Structural basis of SALM3 
dimerization and synaptic adhesion 
complex formation with PTPσ
Sudeep Karki1, Alexander V. Shkumatov2,3, Sungwon Bae4, Hyeonho Kim4, Jaewon Ko4 & 
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Synaptic adhesion molecules play an important role in the formation, maintenance and refinement 
of neuronal connectivity. Recently, several leucine rich repeat (LRR) domain containing neuronal 
adhesion molecules have been characterized including netrin G-ligands, SLitRKs and the synaptic 
adhesion-like molecules (SALMs). Dysregulation of these adhesion molecules have been genetically 
and functionally linked to various neurological disorders. Here we investigated the molecular 
structure and mechanism of ligand interactions for the postsynaptic SALM3 adhesion protein with its 
presynaptic ligand, receptor protein tyrosine phosphatase σ (PTPσ). We solved the crystal structure 
of the dimerized LRR domain of SALM3, revealing the conserved structural features and mechanism 
of dimerization. Furthermore, we determined the complex structure of SALM3 with PTPσ using small 
angle X-ray scattering, revealing a 2:2 complex similar to that observed for SALM5. Solution studies 
unraveled additional flexibility for the complex structure, but validated the uniform mode of action 
for SALM3 and SALM5 to promote synapse formation. The relevance of the key interface residues was 
further confirmed by mutational analysis with cellular binding assays and artificial synapse formation 
assays. Collectively, our results suggest that SALM3 dimerization is a pre-requisite for the SALM3-
PTPσ complex to exert synaptogenic activity.
Neurons form highly complex networks of specific connection patterns through the cellular junctions at synapses. 
Synaptic adhesion molecules are emerging synapse organizers, which are localized at the nerve cell membranes at 
the synaptic cleft, and play a crucial role in the formation, maintenance and refinement of neural  circuits1. Several 
families of synaptic adhesion molecules have been identified, including e.g.  neurexins2,  neuroligins3, synaptic 
adhesion like molecules (SALMs)4, leucine-rich repeat (LRR) transmembrane neuronal proteins (LRRTMs)5, 
leukocyte common antigen-related receptor protein tyrosine phosphatases (LAR-RPTPs)6 and netrin-G ligands 
(NGLs)7. The dysfunction of synaptic adhesion molecules have been proposed to be involved in onset and 
progression of various neurological disorders, which includes autism spectrum disorders, schizophrenia and 
Alzheimer’s  disease8–11.
The SALM family of proteins also known as LRR and fibronectin III domain containing proteins (LRFNs), 
represent a family of LRR-containing synaptic adhesion molecules, with five known members (SALM1-SALM5)4. 
All the SALM proteins share a similar domain architecture consisting of an extracellular region with an LRR 
domain, an immunoglobulin (Ig) domain and a fibronectin III (FnIII) domain followed by a transmembrane 
domain (TM) and a non-structured cytoplasmic  region12. Notably, SALM1-3 contain type I PDZ binding motifs, 
which are absent in SALM4 and  SALM54,12 (Fig. 1a).
SALMs are considered to be postsynaptic adhesion proteins, mostly expressed in the neurons and regulate 
neurite outgrowth and  branching12. In addition, they have been implicated in the regulation and development 
of synapse  formation12–14. SALM3 and SALM5 possess synaptogenic activity, and promote both excitatory and 
inhibitory presynaptic differentiation in contacting  axons15 via trans-synaptic interaction with LAR-RPTPs13,14. 
SALM4 suppresses excitatory synapse development by cis-inhibiting trans-synaptic SALM3-LAR-RPTP 
 adhesion16. Crystal structures of human SALM5-PTPδ, and also SALM2-PTPδ complexes reveal 2:2 heterotetra-
meric trans-synaptic association between the  proteins17–19. We previously reported the crystal structure of mouse 
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SALM5 LRR-Ig domain fragment, and solution structures of SALM3 and SALM5 extracellular  regions20. This 
study revealed that LRR domains of SALM5 are involved in dimerization, and the different structures indicated 
that overall structural features are conserved between SALM2, SALM3 and  SALM520. However, structural details 
of SALM family beyond SALM2 and SALM5 remain to be determined including SALM3 and the molecular 
details of its interaction with LAR-RPTPs.
SALM3 is expressed early during embryonic stage in the brain, whereas the other SALMs are expressed from 
the embryonic stage, and the expression is maintained or increased after  birth21. In vivo studies using SALM3 
knockout  (SALM3−/−) mice displayed markedly reduced excitatory synapse number and locomotor activity, and 
exhibit behavioral hypoactivity, which underlines the importance of SALM3 in excitatory synapse  development14. 
SALM3 interacts with all three known members of LAR-RPTPs (LAR, PTPσ and PTPδ) to induce presynaptic 
 differentiation14. The interaction between SALM3 and LAR-RPTPs is markedly enhanced in the presence of the 
LAR-RPTP mini-exon B (meB)14,20. Besides SALMs, LAR-RPTPs form trans-synaptic complexes with different 
families of postsynaptic adhesion proteins, which include NGL-3, IL1RAcP, neurotrophin receptor TrkC and 
the  Slitrks22,23. The extracellular region of LAR-RPTPs contain three Ig domains, four to eight FnIII domains and 
multiple splicing variants at several sites: mini-exon A (meA) in the Ig2 domain, mini-exon B (meB) between 
Ig2 and Ig3 domain and mini-exon C (meC) located in the FnIII domain (Fig. 1a). In the cytoplasmic region, 
LAR-RPTPs contain two tandem tyrosine phosphatase  domains6,22. The Ig2 and Ig3 domains of PTPδ and PTPσ 
are involved in interaction with the LRR and Ig domains of  SALM517,18.
In this study, we have solved the crystal structure of mouse SALM3 LRR domain and show that it forms a 
dimer that is close to identical to that of SALM5, and the residues that are involved in dimerization and their 
interactions are largely conserved, and our complementary biophysical studies support this. We also solved the 
small angle X-ray scattering (SAXS) structure of SALM3-PTPσ complex that verifies the formation of the 2:2 
trans-heterotetrametric complex between the proteins. Mutational studies with a cell-based binding assay and a 
synapse formation assay confirm the binding mechanism of SALM3 to PTPσ and the identity of the key interface 
residues that are largely the same as for the SALM5-PTPδ interaction. Therefore, we conclude that SALM3 and 
SALM5 interact in similar manner with their LAR-RPTP ligands to induce presynaptic differentiation. Solution 
Figure 1.  Crystal structure and dimer assembly of SALM3 LRR domain. (a) Domain organization of SALMs 
and LAR-RPTPs. Main features are indicated as: Ig, immunoglobulin domain; Fn, fibronectin domain; Tm, a 
transmembrane domain; D, phosphatase domain; LRR, LRR domain; N, LRRNT; C, LRRCT; PDZ, PDZ binding 
motifs. (b) The overall SALM3 LRR domain structure. The missing parts for the LRR domain shown as dashed 
lines, LRRNT and LRRCT-capping domains are colored blue (LRRNT) and red (LRRCT) respectively. The N- 
and C-termini of the protein are marked with ‘Nt’ and ‘Ct’ and the residue number, disulphides are indicated 
in yellow as sticks. (c) Dimeric assembly observed in the crystal structure with one of the subunits shown with 
transparent surface, and N-glycosylation present in the LRRNT Asn25 shown as sticks. On the left structure 
is viewed from the “top” towards the concave side of the LRR dimer, orthogonal to the interface, and on the 
right from the side, glycosylated Asn25 marked. Molecular structure figures were prepared with PyMol, version 
1.5.0.5 (www.pymol .org).
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scattering studies suggest that the dimeric complex has significant conformational flexibility. Our results also 
confirm that dimerization is absolute requirement for induction of synapse formation by the SALM3, similar to 
SALM5, and thus appears to be common for the SALM family proteins involved in synapse formation.
Results and discussion
The structure of the SALM3 LRR domain. The structure of mouse SALM3 LRR domain (Fig. 1b, c) was 
solved at 2.8 Å resolution in space group  P21 (Table 1). The crystals exhibited high degree of twinning, making 
the structure solution demanding (see methods). However, it was possible to obtain a good quality refined model 
once the correct space group was resolved. Four molecules, or two dimers, were present in the asymmetric 
unit of the crystal, one monomer had an N-glycan partly visible in electron density at Asn25 at the N-termi-
nal end of the domain (Fig. 1c). Overall two N-glycosylation sites are predicted to be present in SALM3 LRR 
domain (Asn25 and Asn70), with most of the glycans disordered in the structure, however. The LRR domain 
shows a typical extracellular LRR domain structure, similar to the known SALM5 LRR structure (Supplemen-
tary Fig. S1)20, with an extend β-sheet on the concave side of the structure formed by the seven LRRs (L1-L7) 
(Fig. 1b) of variable length (22–24 residues) with consensus motif of “L1xxL4xL6xL8xxN11xL13” with aliphatic Leu 
or Ile residues mostly occupying positions 1, 4, 5, 6 and 13 and forming the hydrophobic core of each repeat, and 
the absolutely conserved Asn11 hydrogen bonding to the previous repeat. The LRR domain further contains an 
N-terminal LRRNT capping subdomain (residues 17–48) and an α-helical C-terminal LRRCT capping domain 
(residues 228–278) (Fig. 1b,c), which are conserved in the vertebrate extracellular LRR domain  family24. Both 
the LRRNT and LRRCT subdomains of SALM3 are stabilized by two disulphide bridges; in the LRRNT between 
Cys17-Cys27 and Cys21-Cys34, and in the LRRCT between Cys238–Cys257 and Cys240-Cys278. Cys278 also 
is the last residue of the whole LRR domain. A flexible loop (residues 216–227) is present between the 7th LRR 
and the LRRCT, not visible in the SALM3 crystal structure (Fig. 1b, c). The possible functional significance of 
this loop remains unknown, as its not involved in LAR-RPTPs recognition at least in SALM5-PTPδ complex 
 structures17,18, while such an extension might be expected to have some functional significance, as e.g. in the case 
of platelet glycoprotein IB alpha LRR  domain25.
Dimerization through the LRR domain is a defining feature of the SALM family. The SALM3 
LRR domain forms a dimer similar to those observed for SALM5 and SALM2 crystal  structures17,18,20 (Fig. 1). It 
appears that the SALMs form a highly conserved dimeric structure based on the known structures of SALM2, 
SALM3 and SALM5 and our data on SALM1  oligomerization20, and the overall sequence conservation of the 
interface residues in the protein family (Supplementary Fig. S2, Table S1). The SALM3 LRR structure and dimer 
interface are close to identical to that of SALM5 (Fig. 2, Supplementary Fig. S1, Table S1)20. The hydrophobic 
interactions and hydrogen bonding networks are conserved at the interface with Gln131 and Arg107 forming 
Table 1.  Crystallographic data collection and refinement statistics. a Statistics for highest resolution shell are 
given in parentheses.
Data collection parameters
Beam line DLS I03
λ (Å) 0.97625
Temperature (K) 100
Space group P21
Unit cell
a, b, c (Å) 31.45, 132.16, 134.18
β (°) 90.1
Resolution (Å) 50–2.8
Observations 158,799
Unique 26,991
Rmerge (%)a 17.5 (119)
CC(1/2)a 99.5 (70)
I/ (I)σa 9.0 (2.1)
Refinement
Resolution (Å) 50–2.8
Rwork/Rfree (%) 26.91/28.50
No. of reflections/Rfree-set reflections 26,902/1,347
Average B-factor (Å2) 88.27
No. of atoms (protein) 7,258
r.m.s.d bond lengths (Å) 0.006
r.m.s.d bond anlges (°) 0.88
Ramachandran plot (favoured/outliers) (%) 92.24/0.6
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hydrogen bonds across the dimer interface to Asn156 of the other monomer and vice versa (Fig. 2, Table S1). 
The SALM3 LRR domain, like SALM5 and SALM2 forms an antiparallel side-by-side dimer, with a rather small 
interface with buried surface area of 1,001 Å2. The interface consists of the “one-layer” central hydrogen bond-
ing network (Fig. 2) described above, and hydrophobic interactions formed by the N- and C-terminal regions 
(Fig. 2). The dimer species is however very stable in solution for both SALM3 and SALM5, and also SALM1 
based on our  observations20. Monomeric species have not been observed in vitro. Here, we analysed the oligo-
meric state in solution for both the LRR domain and LRR-Ig construct for SALM3 by size exclusion chromatog-
raphy-coupled multiangle static laser light scattering (SEC–MALLS) (Fig. 3a, b). Both appear as dimers based 
on observed molecular weights of ca. 60 and 80 kDa (Fig. 3a, b); twice the size of molecules weights calculated 
from sequence (30,9 and 40 kDa). Thus, these measurements verified that the LRR domain is sufficient alone 
for stable dimer formation. Comparison of the SALM3, SALM5 as well as SALM2 dimers reveals highly similar 
structures with r.m.s.d. values of 0.691 and 0.758 Å for the LRR domains of SALM5 and SALM2 against SALM3 
structure, respectively. Differences can be seen mainly in the conformation of the LRRNT capping region (Sup-
plementary Fig. S1). Thus, we conclude that the dimerization mechanism through the LRR domains is conserved 
in the family, generating a unique dimeric post-synaptic LAR-RPTP ligand, with possible functional impli-
cations. Interestingly all the other characterized LAR-RPTP ligands (Slitrks, IL1RAPL1 and TrkC and NGL-
3)26–29 are monomeric. Dimerization of SALMs might be a way of regulation of the function and induction of 
presynaptic signaling by LAR-RPTPs, as in the case of SALM3 and SALM5 biological function depends on the 
 oligomerization17,18 (see below), and SALM4 regulates the function of SALM3 by cis-inhibition, most likely 
through heterodimer  formation16. Function of SALM2 remains unclear, but it appears to be able to bind the 
LAR-RPTP  receptors18, whereas the function of SALM1 appears quite different, with reported involvement in 
actin mediated post-synaptic neurexin clustering, and no synapse formation activity  reported30.
The solution structure of SALM3-PTPσ complex. In order to understand the binding mode of SALM3 
to its PTPσ ligand, we have characterized the solution structure of the  SALM3LRR-Ig-PTPσIg1-Ig3 complex using 
size exclusion chromatography coupled with SAXS (SEC-SAXS). The SEC-profile of SALM3-PTPσ complex 
shows a single major peak, and the frames (350–365) with similar Rg-values, as calculated from the X-ray scat-
tering intensities were averaged for further analysis (Fig. 3c). The  SALM3LRR-Ig and PTPσIg1-Ig3 structures were 
modelled based on the known crystal structures, as described in the methods. Rigid body fitting of the complex 
and ab initio envelope modelling were done against the obtained solution scattering data. The complex structure 
was modelled by rigid body fitting, with the LRR dimer structure as one rigid body and each SALM5 Ig-domain 
with its respective bound PTPσ ligand Ig1-Ig3 structure as the two other rigid bodies (Figs. 1, 3), The starting 
model was based on the SALM5-PTPδ complex crystal structure (PDB 5XNP)17 and the final rigid body refine-
ment results against the SAXS data demonstrate that a 2:2 complex between SALM3 and PTPσ is formed similar 
to SALM5. Both 2:2 complex models with P1 and P2 symmetry fit the data well with  X2-values of 1.7 and 2.5 
respectively (Fig. 3d–f and Supplementary Fig. S3). This is further supported by the ab initio envelope calcula-
tions that fit well with the rigid body models (Fig. 3g, h). Both methods give a result that fit a 2:2 complex best. 
We further confirmed that 1:1 and 2:1 complexes do not fit to the data (Supplementary Fig. S3).
It should be noted that while it is possible to obtain a good fit to the model with P2 symmetry constraint, we 
stress that due to the limited resolution of SAXS data, the model is likely representing an average snapshot of 
a number of conformations present in solution. This is further confirmed by the fact that the fit can be slightly 
improved if no symmetry constraints are used, indicating certain degree of flexibility in the modelled regions. 
Figure 2.  The dimer interface of SALM3 LRR domain. Residues contributing to the interface either by 
hydrogen bonds (dashed lines) or hydrophobic interactions are indicated. One monomer (top) is shown in 
cyan, and the other in grey with N-terminal capping LRRNT-subdomain in blue and LRRCT-subdomain in red, 
disulphides indicated in yellow as sticks. Figure prepared with PyMol, version 1.5.0.5 (www.pymol .org).
5
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11557  | https://doi.org/10.1038/s41598-020-68502-4
www.nature.com/scientificreports/
Figure 3.  Solution structure of the complex between SALM3 and PTPσ. (a) The oligomeric state of SALM3 
LRR domain and, (b) SALM3 LRR-Ig constructs were characterized by SEC–MALLS. Calculated Mws (right 
Y-axis) are plotted over the dRI signal peaks for the proteins; average observed molecular weights were 59.5 kDa 
and 82.4 kDa for LRR and LRR-Ig constructs, respectively. (c) The SEC-SAXS profile of SALM3-PTPσ complex 
(solid line) and BSA (dashed line). Frames (350–365, shaded regions) were selected for further SAXS analysis. 
Rg-values (left Y-axis) were plotted over averaged X-ray scattering intensities (right Y-axis). (d) Scattering 
intensity profiles with the corresponding fit to SALM3-PTPσ complex models generated with rigid body 
modeling in CORAL in P1 and P2 symmetry. Experimental SAXS profiles were appropriately displaced along 
the logarithmic axis for better visualization and overlaid with corresponding fits. (e, f) show the SALM3-PTPσ 
complex models in P2 and P1 symmetry, respectively. SALM3 LRR and Ig domains are colored blue, PTPσ Ig1-3 
domains are colored orange and modelled glycans are colored by atom (carbon: white, oxygen: red and nitrogen: 
blue). (g, h) Superimposition of the ab initio calculated envelope models (grey) and SALM3-PTPσ rigid body 
complex models with P2 and P1 symmetry, respectively. (i) Schematic model for the 2:2 interaction complex 
of SALM3 with PTPσ at the synapse. The SALM LRR domain repeats and Ig domain are shown in blue, orange 
ellipses indicate the Ig domains, additional structures not present in the SALM3 complex structure model are 
shown in grey. Grey rectangles indicate Fn-domains on both proteins, and grey squares (on presynaptic side) 
the PTP phosphatase domains “N” an “C” denote N-terminus and C-terminus. For further clarity, proteins and 
domains of second SALM3:PTPσ complex are marked as SALM3′ and LRR’. Molecular structure figures were 
prepared with PyMol, version 1.5.0.5 (www.pymol .org).
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Figure 4.  Mutational studies of SALM3-PTPσ interface. (a) The SALM3-PTPσ complex model showing the 
conserved residues in SALM3 LRR-Ig model and the binding interface to PTPσ in the 2:2 dimeric complex, 
orthogonal to the SALM3 dimer interface (left), and from the side with PTPσ Ig domains and meB site indicated 
in SALM3-PTPσ 1:1 complex model (right). Red color indicates the most conserved residues in SALM3 LRR-Ig 
as calculated by  CONSURF44, PTPσ is colored in teal. (b) Interaction sites between SALM3 and PTPσ based 
on the SALM5-PTPδ crystal structure (PDB ID: 5XNP), are shown as labeled in the figure. (c) Close-up view 
of the predicted interacting sites for the SALM3-PTPσ complex, as labeled in the figure; from the left Site I, Site 
II and Site III. Residues involved in hydrogen bonding (dashed line and hydrophobic interactions are shown, 
colored as in a) and for visual clarity non-carbon atoms color-coded according to atom (nitrogen: blue, sulphur: 
yellow, oxygen: red. (d) Cell binding assay of soluble PTPσ-Fc (0–250 nM) to SALM3 on the HEK293T cells. 
Detected in-cell Western blot signals (right) and equilibrium binding curve (left). (e) Cell-based binding study 
of the surface expressed WT SALM3 and mutants to PTPσ on the HEK293T cells. Detected in-cell Western 
blot signals (right) and binding intensities of PTPσ to WT SALM3 and mutants (left). (f) Controls for the cell 
binding assay. From right; plain (HEK293T) cells (–/–), HEK293T cells with SALM3 transfected (SALM3/–), 
plain HEK293T cells with ligand PTPσ-Fc added (–/PTPσ), HEK293T (SALM3 expressed) with ligand PTPσ-Fc 
added (SALM3/PTPσ-Fc) and HEK293T (SALM3 expressed) with ligand NRXN-α-Fc added (SALM3/
NRXNα). Molecular structure figures were prepared with PyMol, version 1.5.0.5 (www.pymol .org).
◂
We have also previously shown that the position of the Ig-domain is flexible relative to the LRR domain dimer for 
both SALM3 and  SALM520. Taken together, our results suggest 2:2 stoichiometry for the SALM3 LRR-Ig:PTPσ 
Ig1-Ig3 complex in solution, and we propose a schematic model for the orientation of the complex organization 
in the synaptic cleft (Fig. 3i).
Thus, we here show that SALM3 forms a complex with the presynaptic PTPσ receptor with a similar mecha-
nism to SALM5 binding to PTPδ, and that we observe that the structure exhibits certain amount of flexibility that 
may be requirement for the molecular environment in the synaptic cleft between the two cellular membranes. 
Based on the SAXS data, we further validated the interaction sites in the SALM3-PTPσ complex by site-directed 
mutagenesis and cell-based binding and heterologous synapse formation assays.
Mutational analysis of SALM3-PTPσ interface. The recent SALM5-PTPδ complex crystal structures 
at 3.7 Å and 4.2 Å resolution showed that the LRRCT-region and Ig-domain of SALM5 interact with the Ig2 
and Ig3 domains of PTPδ, and the presence of meB sequence enhanced the  interaction17,18. We also reported in 
our earlier  study20 using surface plasmon resonance (SPR) that the interaction of SALM3 and PTPσ is enhanced 
by ten-fold in presence of meB. The  Kd for SALM3 interaction with PTPσ-meB + by SPR was measured to be 
2.2 µM20.
Multiple sequence alignment of SALM3 and SALM5 sequences (Supplementary Fig. S2), and the amino acid 
conservation plotted on the SALM3-PTPσ complex model, and comparison of aligned SALM2, SALM3 and 
SALM5 complex structures (Fig. 4a–c, Supplementary Fig. S4) show that the PTPσ interacting residues of SALM3 
are mostly conserved in SALM3 and SALM5 in the vertebrates (Fig. 4a; Supplementary Fig. S2, Table S2). In 
addition, in the LRR domain dimer structure of SALM3, the concave surface shows large number of conserved 
residues between SALM3 and SALM5 based on sequence analysis (Fig. 4a)20. This might indicate a potential 
binding site, the ligand for which remains to be identified.
Based on the sequence analysis, and in particular the SAXS structure of SALM3-PTPσ complex, we sug-
gest that the binding interface of SALM3-PTPσ is similar to SALM5-PTPδ, with the observed dependence on 
the presence of  meB14,20, structural alignment of SALM3 model to SALM2, and SALM5 complexes indicate 
the interaction sites are also structurally highly conserved (Supplementary Fig. S4). In order to verify this, we 
generated several deletion and point mutations to SALM3 extracellular domain at the SALM3-PTPσ ligand 
interface modelled based on the binding interface interactions of SALM5-PTPδ structure. The wild-type (WT) 
and mutant SALM3 proteins were expressed in HEK293T cells, and tested for interaction with PTPσ-Fc fusion 
protein using an in-cell western binding assay (Fig. 4d, e). Initially, we measured the apparent binding affinity 
of soluble dimeric PTPσ-Fc to SALM3 on the cell surface to be 22.32 ± 5 nM (Fig. 4d). It should be noted that 
this is an overestimate of the 1:1 affinity, due to the avidity effects arising from to the use of a dimeric Fc-fusion 
construct. The 1:1 binding affinity for the interaction is 2.2 µM, as noted  above20. The negative controls showed 
no detectable signal (Fig. 4f), which confirmed the specificity of the assay. To assess the effect of the point muta-
tions, we used 150 nM PTPσ-Fc.
Firstly, SALM3 ΔLRR, SALM3 ΔLRR + ΔFn and SALM3 ΔIg-Fn domain deletion mutants were expressed on 
the surface of HEK293T cells, but showed no interaction with PTPσ (Fig. 4e). The cell-based binding studies on 
SALM3 deletion mutants verified that both the LRR and Ig-domain of SALM3 are involved and necessary for 
the PTPσ interaction, and neither alone is enough for binding to the PTPσ. Point mutations on the SALM3 LRR 
and Ig-domains were analysed for PTPσ interaction to probe and verify more closely the importance of binding 
interfaces of SALM3-PTPσ complex. The surface expression and secretion was verified by immunofluorescence 
and western blot detection of the variants as described in the Methods and Supplementary Fig. S5 and S6.
The binding interface in SALM3-PTPσ complex is formed by three interaction sites (Fig. 4b, Supplementary 
Table S2), similar to SALM5-PTPδ (PDB 5XNP, 5XWT)17,18. In site I the SALM3 LRRCT forms an interface 
with the Ig2-domain of PTPσ, in site II SALM5 Ig-domain interacts with Ig3-domain of PTPσ and in site III 
the SALM3 Ig-domain binds to Ig2-domain of PTPσ17. We generated mutations in SALM3 on these three sites 
(Fig. 4b, c) in order to validate the SALM3 complex structure.
In the case of SALM3-PTPσ complex, in site I, Arg247 (SALM5 Arg253) forms hydrogen bond with the PTPσ 
Gln202 and back bone carbonyl of Val225 (Fig. 4c). In the cell-based binding assay SALM3 Arg247Ala mutant 
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shows no interaction with PTPσ (Fig. 4e). This confirms its critical importance for the interaction for SALM3 
with PTPσ. In an earlier  study18, it was reported that SALM5 Arg253Ala decreased the binding affinity with PTPδ 
eight-fold compare to the wild-type (WT). The site consists of additional hydrophobic interactions by residues 
Pro212, Cys 246, Leu249 and Trp250 in SALM5 with PTPδ, corresponding to SALM3 Pro210, Cys240, Leu243 
and Trp244 residues, in equivalent positions (Supplementary Table S2). Sequence analysis further confirms that 
the residues are highly conserved in SALM3 and SALM5 (Supplementary Fig. S2 and Table S2). Essentially all 
the PTPσ residues involved are conserved on all three interfaces (Supplementary Fig. S7).
In site II, SALM3 Arg285 (SALM5 Arg291) forms an ion pair with PTPσ Asp275, and hydrogen bonds to 
the main chain carbonyl group on Thr277 of PTPσ (Fig. 4c). These interactions are conserved between the two 
complexes. However, not all interface residues in the SALM Ig-domains are conserved. SALM3 Leu305 (Arg311 
in SALM5) binds to a hydrophobic pocket surrounded by Met282, Tyr266 and Glu279 side chains (Fig. 4c). This 
Figure 5.  Analysis of SALM3 variants in heterologous synapse formation assay. (a) Representative images 
of the heterologous synapse-formation activities of SALM3 variants. Cultured Neurons were cocultured 
from DIV9 to DIV11 with HEK293T cells expressing the indicated WT-SALM3 protein, its point mutants, 
or deletion variants. Neurons were then stained with antibodies against HA (blue) and synapsin (red). Scale 
bar = 10 μm (applies to all images). (b) The synapse-forming activity was quantified by measuring the ratio of 
synapsin staining intensity (red) to HA immunoreactivity intensity (blue). Data are presented as mean ± SEM 
(****p < 0.0001 and ####p < 0.001; n = number of neurons as follows: WT, n = 17; R107S, n = 11; R107S/Q131A, 
n = 13; R247A, n = 17; L282R, n = 16; L282R/R285A, n = 22; R285A/L305A, n = 17; H313A/L321A, n = 16; T354R/
E359A, n = 14; ΔLRR, n = 17; ΔIg-FNIII, n = 17; and ΔLRR/ΔFNIII, n = 15). Scale bar, 10 μm (applies to all 
images). SALM3 variant for Sites I, II and III are coloured in red, blue and green in the bar chart, respectively.
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is different in SALM5 where the Arg311 hydrogen bonds to adjacent PTPδ Tyr257 and backbone carbonyl groups 
at Glu270-Asp271. These amino acid differences at the binding site might lead to slight changes in specificity 
or affinity in vivo.
In addition, at site II in the SALM3 complex Leu282 (SALM5 Leu288) forms hydrophobic interactions with 
PTPσ Met305 and the peptide main chain at the turn residues 306–307 of the PTPσ Ig3-domain (Fig. 4c). The 
cell-based binding measurements of SALM3 Arg285Ala-Leu282Arg and Arg285Ala-Leu305Ala double mutants 
with PTPσ showed no signal for interaction (Fig. 4e), and thus verify the importance of site II and Arg285, Leu282 
and Leu305 for PTPσ binding. In previous studies SALM5 Leu288Ala mutation was reported to decrease affinity 
by 10-fold18, and SALM5 Lys309 and Arg311 when mutated to Asn and Thr to introduce an N-glycosylation site 
in place of Lys309 also abolished  binding17.
In site III of the model, Glu359 (SALM5 Glu365) forms hydrogen bond with the PTPσ Thr153, and a salt 
bridge to PTPσ Lys144. SALM3 Leu321 and His313 (SALM5 Leu327 and His319) form hydrophobic interactions 
with Asp138, Met139 and Ala157 of PTPσ (Fig. 4c). SALM3 Thr354 is also part of the interface and packs against 
Leu155 of PTPσ. An earlier  study17 reported that based on Ala-scanning mutagenesis that SALM5 Ser360Ala-
Se329Ala double mutant (Ser360Ala equal to SALM3 Thr354) significantly reduced the interaction with  LAR18. 
Our cell-based binding study showed that SALM3 Leu321Ala-His313Ala double mutation abolishes the interac-
tion with PTPσ, and SALM3 Thr354Arg-Glu359Ala double mutant decreases binding towards PTPσ by ~ 50% 
but did not abolish the interaction (Fig. 4e). Thus, in site III the hydrophobic interactions by Leu321 and His313 
appear to be most critical for the affinity in SALM3 of the residues at this interface (Fig. 4c, e and Supplementary 
Table S2). Overall, all three sites observed as binding interfaces for SALM5 appear to be functionally equivalent 
in SALM3, and our mutational data on the interfaces nicely complements the earlier limited mutational studies 
on  SALM517,18.
Finally, for SALM5, it was reported that the Asn158Ala and Gln134Asn SALM5 mutations (equivalent to 
SALM3 residues Asn156 and Gln131) that interfere with the LRR dimerization hardly affect the binding to 
PTPδ18. Our cell-based binding studies show that the SALM3 Arg107Ser-Gln131Ala double mutation at the 
dimer interface interferes directly with PTPσ binding (Fig. 4e), which is in contrast to SALM5 results. This sug-
gests dimerization on cell surface could be direct pre-requirement for activity, at least in the case of SALM3, and 
potentially based on the highly similar interaction also in SALM5. We also verified that the purified Arg107Ser-
Gln131Ala mutant protein actually is monomeric in solution, while two other double mutants Leu282Arg-
Arg285Ala and Thr354Arg-Glu359Ala where dimeric and expressed and behaved as the wild type SALM3 
(Supplementary Fig. S8).
The effect of SALM3 variants on presynaptic differentiation. Since SALM3 functions as a syn-
apse organizer inducing presynaptic differentiation through binding to presynaptic LAR-RPTPs, we tested the 
effect of the SALM3 mutations on presynaptic differentiation activity using heterologous synapse-formation 
assays. SALM3 mutants expressed in HEK293T cells were cultured with hippocampal neurons (DIV9), and the 
presynaptic differentiation was detected by immunostaining against the presynaptic marker synapsin I (Fig. 5). 
The synaptogenic activity of SALM3 was clearly detected with the WT SALM3, but the interface mutants target-
ing the SALM3-PTPσ interaction abolished synapsin I clustering (Fig. 5). In addition, Thr354Arg-Glu359Ala 
double mutant at site III showed significantly decreased activity, despite exhibiting 50% residual binding at 
saturating concentration towards the PTPσ-Fc (Fig. 4e). Also the Leu282Arg mutation alone at site II was suf-
ficient to compromise the SALM3 activity in inducing presynaptic differentiation (Fig. 5). In case of SALM5, it 
was previously  reported18 that SALM5 Arg253Ala (Site I of SALM5-PTPδ complex), SALM5 Leu288Ala (Site II) 
and SALM5 Ile358Ala (Site III) mutants severely reduced the synaptogenic activity. In addition, the Arg107Ser-
Gln131Ala SALM3 mutant that interferes with the SALM3 LRR dimerization also abolished the synaptogenic 
activity (Fig. 5). These results suggest that SALM3 mediated dimerization is critical for interaction with PTPσ 
and the formation of SALM3-PTPσ trans-synaptic signaling complex to induce presynaptic differentiation. 
Overall, the binding assays results are well correlated with data obtained from heterologous synapse formation 
analyses. This further suggests that all interactions that are important for the complex formation with PTPσ are 
also required for the synaptogenic activity. Thus the results verify the biological significance of all the three inter-
action sites, and the fact that the described SALM3-PTPσ interactions are necessary and sufficient for presynap-
tic differentiation by SALM3. Recently Xie et al.31 reported that LAR D1 phosphatase domains can dimerize to 
promote clustering and activation of synaptic differentiation. We suggest that the dimeric 2:2 complex formation 
by SALMs on binding to LAR-RPTPs in turn may promote the intracellular homophilic interactions of LAR-
RPTPs and further activation of presynaptic differentiation.
conclusions
SALM3 was the first protein in the SALM-family to be characterized as a ligand for presynaptic LAR-RPTPs14. 
We have now resolved its molecular mechanism of action and mode of oligomerization, which we conclude are 
similar with SALM5. Taken together, we conclude that dimerization might be a universal mechanism that is 
conserved across all SALM family proteins and that LAR-RPTP recognition occurs via the same binding inter-
faces. We hypothesize that SALM3 dimerization promotes presynaptic differentiation by bringing the LAR-RPTP 
receptors together and enhancing their clustering. Further studies are warranted to systematically test how SALM 
dimerization is involved in mediation of various synaptic functions and LAR-RPTP activation.
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Materials and methods
Cloning, protein expression and purification. Mouse SALM3 LRR (residues 17–284) was cloned into 
Drosophila pRMHA3 expression  vector32 with CD33 signal sequence at the N-terminus and a C-terminal Fc-
tag preceded with a Prescission protease cleavage site. The cDNA for SALM3 was obtained from ImaGenes 
GmbH. The cloning and protein purification of SALM3 LRR-Ig (residues 17–367) and mouse PTPσ Ig1-3-meB+ 
(resdiues 33–331) have been described in  earlier20. For cell-based binding assays, the mouse SALM3 LRR-Ig-
Fn (residues 17–510) and the deletion mutants SALM3 LRR (residues 17–284) “ΔIg-Fn”, SALM3 Ig (residues 
280–367) “ΔLRR + Fn” and SALM3 Ig-Fn (residues 280–502) “ΔLRR” were cloned in the pDisplay plasmid vec-
tor. The constructs contained an N-terminal HA-tag followed by the cloned SALM3 sequence, and at the C-ter-
minus Myc-tag followed by transmembrane domain. For mutational studies, we used site directed  mutagenesis31 
to mutate the plasmid constructs of SALM3 LRR-Ig-Fn. The oligonucleotide pairs used for the cloning and 
mutagenesis are listed in Supplementary Table S4.
For SALM3 LRR, the protein expression was verified by transient transfection and western blot detection 
with goat anti-human polyclonal horse radish peroxidase (HRP) conjugated antibody (Abcam ab98567). A stable 
Drosophila S2 cell line for SALM3 LRR expression was then generated for the protein purification, and protein 
was expressed in standard manner as described  previously20. The protein with the C-terminal Fc-fusion was 
affinity purified with protein-A sepharose (Invitrogen). Samples were eluted with 0.1 M glycine pH 3.0 directly 
to a neutralizing buffer, with final composition of 60 mM Tris pH 7.4, 300 mM NaCl. The tagged proteins were 
incubated with Precission protease for 16 h at 4 °C to remove the Fc tag. Precission protease was produced as a 
GST fusion in Escherichia coli BL21 (DE3) from pGEX-6P-1 vector (Addgene). The cleaved Fc-fusion protein 
were passed through a protein-A column, and flow-through containing the cleaved SALM3-LRR was collected 
and gel filtered with Superdex 75 10/300 (GE Healthcare) in 60 mM Tris pH 7.5, 300 mM NaCl and concentrated 
and stored at − 80 °C for further use.
Biophysical characterization. SEC–MALLS was used for the biophysical characterization of size dis-
tribution and oligomerization of SALM3 LRR domain construct. The measurements were done at flowrate of 
0.5 ml/min over an S-75 Superdex 10/300 column (GE Healthcare) in 20 mM Tris pH 7.4, 150 mM NaCl with a 
HPLC system (Shimadzu) and a MiniDAWN TREOS light scattering detector, and Optilab rEX refractive index 
detector (Wyatt Technology Corp.), Sample (100μL) was injected at 1.5 mg/ml. Data were then analyzed with 
ASTRA 6 software (Wyatt Technology Corp.).
Crystallization and structure determination and refinement. The SALM3 LRR construct was con-
centrated to 7.2 mg/ml and exchanged to 20 mM Tris pH 7.4, 100 mM NaCl for crystallization. Thin plate-like 
crystals appeared from 0.17 M ammonium sulfate pH 7.5, 25% w/v PEG 4,000, 10% glycerol at + 20 °C. Crystals 
were harvested directly from the drop and flash frozen for data collection. The crystals diffracted to 2.8 Å and 
crystallized in space group  P21, and were twinned (pseudo-orthorhombic) due to the β-angle being almost equal 
to 90° (Table 1) with high twin-fraction of ca. 34% with the twinning operator h, − k, − l and with two dimers 
in the asymmetric unit (Table 1). The twinning affected the quality of maps and model unavoidably to some 
extend and complicated the refinement process, however final electron density was of satisfactory quality (Sup-
plementary Fig. S9).
The SALM3 crystal structure was solved by molecular replacement with the CCP4 package and  PHASER33. 
An initial solution for the SALM3 LRR was found using the LRR domain of SALM5 (PDB 6F20)20 as a template. 
After molecular replacement and initial refinement with  REFMAC34, the R-factors for the initial LRR domain 
model were  Rwork/Rfree = 41.2%/46.9%. The model was further refined with  PHENIX35 and  BUSTER36 and rebuild 
with  COOT37. The final model refined with BUSTER had R-factors of 26.91/28.50% (Table 1).
Small-angle X-ray scattering data collection and analysis. SAXS data on the SALM3 LRR-Ig and 
PTPσ complex was measured by the SEC-SAXS method at Diamond Lightsource on the B21 beamline. For 
SALM3 LRR-Ig and PTPσ complex preparation, SALM3 LRR-Ig and PTPσ were mixed in the molar ratio of 1:1.2 
of SALM3 LRR-Ig (60 µM) and PTPσ (80 µM) in total volume of 50 µl, followed by incubation at 4 °C for 1 h. 
Sample compartment and exposure cell were cooled to 4 °C. Superdex 200 PC 3.2/30 (GE Healthcare) column 
was used with flow rate of 0.5 ml/min in 30 mM Tris HCl pH7.5, 150 mM NaCl. Data processing was performed 
using ScÅtter38 and  DATASW39. Particle shapes at low resolution were reconstructed ab initio by  DAMMIN40 
in P1 with P(r) function generated from the data truncated to 0.25 Å−1. A total of 10 independent reconstruc-
tions were performed, and the models were averaged with the program  DAMAVER41. Rigid body modeling was 
performed using  CORAL42, where available partial crystal structures were treated as rigid bodies while missing 
residues were modelled ab initio as a Cα-chain by the software. The final model was converted to a full all-atom 
model using FULCHER tool (Shkumatov A. et al., unpublished). The modeling was done with either P1 or P2 
symmetry. Porod and dimensionless Kratky plots were calculated for estimation of  Dmax and the overall com-
pactness of the models (Supplementary Fig. S3).
Homology modeling and conservation analysis. Homology models of SALM3 LRR-Ig and PTPσ Ig1-
Ig3 structures for SAXS studies and interface analysis were generated based on the known SALM5 (PDB 6F2O) 
and PTPδ crystal structures (PDB 5XNP) using SWISS-MODEL (https ://swiss model .expas y.org/)43. Sequence 
conservation was analysed and plotted on the SALM3 structure using  CONSURF44 based on multiple sequence 
alignment of selected SALM3 and SALM5 LRR-Ig domain amino acid sequences from Mus musculus, Homo 
sapiens, Felis catus, Latimeria chalumnae, Danio rerio, and Callorhinchus milii with UniProt/TrEMBL or NCBI 
sequence IDs Q80XU8, Q6PJG9, M3W7N9, H3BGZ7, B0S5R7 and XP_007909247.1 for SALM3 and Q8BXA0, 
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Q96NI6, A0A337S1F8, H3A0X4, F1Q9H7 and A0A4W3GIX7 for SALM5. The SALM3 LRR-Ig and the PTPσ 
models were superimposed with the SALM5-PTPδ complex crystal structure (PDB 5XNP), to generate the ini-
tial SALM3-PTPσ complex model used as a starting point for SAXS analysis. Multiple sequence alignments were 
generated with  MAFFT45, and the alignment figures developed using  Aline46.
cell-based binding assays. We employed the in-cell western blot  method47 to detect the SALM3 and 
PTPσ interaction on cell surface with the Odyssey Infrared Imaging System (LI-COR Biosciences) follow-
ing manufacturer’s recommendations. In this assay, SALM3 constructs were expressed in HEK293T cells and 
PTPσ-Fc was added on the cells in a 96-well plate and the binding was detected with anti-human Fc antibody 
and signal per well was read with the Odyssey Imaging system.
For transfection, HEK293T cells were grown to 90% confluency on a T75 flask using DMEM media with 10% 
FBS (Thermo Fisher Scientific) at 37 °C and 5%  CO2. Cells were seeded into a poly-L lysine-coated 96 well plate 
at approximately 20,000 cells/well and allowed to grow 24 h at 37 °C until the confluency was 90%. After 24 h, 
the cells were transfected with SALM3-pDisplay plasmids (400 µg/well) and polyethylenimine (1.2 µg/well). The 
transfected cells were incubated at 37 °C for 48 h. The SALM3 fusion protein expression in transfected cell was 
detected with Floid™ Cell Imaging system (Thermo Fisher Scientific) using immunofluorescence.
For immunofluorescence detection, transfected cells were fixed under non-permeabilizing conditions with 
4% paraformaldehyde (PFA) for 20 min and blocked at room temperature with 1xPBS buffer containing 1% BSA 
for 60 min, followed by addition of 1:300 dilution primary antibody (rabbit anti-HA, Santa Cruz) and incuba-
tion for 30 min with show shaking at room temperature. The cells were stained with 1:500 dilution secondary 
antibody (Alexa 488 anti-rabbit, Molecular probes), and the expression was detected with Floid™ Cell Imaging 
system to verify the surface expression of proteins (Supplementary Fig. S5).
For in-cell western blot experiment, SALM3 transfected HEK293T cells were blocked with EGB  buffer48 
(10 mM HEPES pH 7.2, 168 mM NaCl, 2.6 mM KCl, 2 mM  CaCl2, 2 mM  MgCl2, 10 mM D-glucose, and 5% BSA) 
for 2 h at room temperature with slow shaking. Blocking buffer was removed and cells were covered in 50 µl of 
PTPσ-Fc diluted in EGB buffer with 1% BSA. The cells were incubated overnight at 4 °C with gentle shaking. Cells 
were further treated with 1:200 dilution of secondary antibody (goat anti-human IgG IRDye 800CW), and the 
SALM3 and PTPσ binding intensity was detected using LI-COR Odyssey (169 µm resolution, medium quality) 
with channel (800 nm) intensity of 8. For the binding assay a concentration series of PTPσ-Fc (1–250 nM) was 
used, and 150 nM PTPσ-Fc (close to saturation) was used for mutational studies.
Heterologous synapse-formation assays. HEK293T cells were transfected with the indicated mutants 
and the WT SALM3 cloned in pDisplay vector (Thermo Fisher Scientific; listed in Table S4). After 48 h, trans-
fected HEK293T cells were trypsinized, seeded onto cultured hippocampal neurons at DIV9, and then coimmu-
nostained with antibodies against  synapsin49 at DIV11. Images were acquired by confocal microscopy (LSM700, 
Carl Zeiss). For quantifications, the contours of transfected HEK293T cells were chosen as the ROI. The fluo-
rescence intensities of synaptic marker puncta, normalized with respect to the area of each HEK293T cell were 
quantified for both red and green channels using MetaMorph Software (Molecular Devices). Surface expression 
was verified as explained in the Supplementary Fig. S10. All data are expressed as means ± SEM. All experiments 
were repeated using at least three independent cultures and data were evaluated statistically using a nonpara-
metric Kruskal–Wallis test, followed by Dunn’s multiple-comparison test for post hoc groups comparisons (n 
values used are indicated in the figure legends). Significance was indicated with an asterisk (compared with a 
value from control group) or hashtag (compared with a value from SALM3 WT-group).
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